Objectives: The centrifugal ultrafiltration-high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) method was established to determine the free perampanel (PER) concentration in children with epilepsy.
Methods: Free PER concentration was obtained using centrifugal ultrafiltration devices. The internal standard was PER-D5. The method was investigated for selectivity, carryover, lower limit of quantification, calibration curve, accuracy, precision, matrix effects, recovery, and stability. The Spearman's correlation coefficient was used to evaluate the correlation between the free and total PER concentrations. A nonparametric test was used to estimate the effects of PER along with other antiepileptic drugs on the total and free PER concentrations.
Results: The free PER concentration was positively correlated with the total PER concentration in the 57 plasma samples ( = 0.793 > 0, < 0.001). Additionally, the free PER concentrations were significantly ( < 0.05) increased in valproic acid (VPA) co-therapy (9.87 ± 5.83) compared with non-VPA co-therapy (5.03 ± 4.57).
Conclusions: The proposed method is efficient, sensitive, and suitable for detecting free PER concentrations in children with epilepsy. Simultaneously, the free PER concentration response to clinical outcomes in children with epilepsy was more clinically significant, particularly when combined with VPA.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11336813 | PMC |
| http://dx.doi.org/10.1016/j.heliyon.2024.e35734 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Long-term efficacy and safety of perampanel monotherapy in patients with newly diagnosed or currently untreated recurrent focal-onset seizures: Results from the open-label extension phase of FREEDOM (Study 342).
Epilepsy Res
December 2024
Korea University, Guro Hospital, Seoul, Republic of Korea.
Objective: FREEDOM (Study 342; NCT03201900) assessed the long-term treatment effect of perampanel monotherapy in adolescent and adult patients (12-74 years of age) with untreated focal-onset seizures (FOS), with or without focal to bilateral tonic-clonic seizures (FBTCS).
Methods: In the Core Study, after a 4-week Pretreatment Phase, perampanel was up-titrated to 4 mg/day during a 6-week Titration Period followed by a 26-week Maintenance Period. Patients experiencing seizure(s) during the 4-mg/day Maintenance Period could have perampanel up-titrated to 8 mg/day over 4 weeks then could enter the 26-week 8-mg/day Maintenance Period.
Impact of Perampanel for First-Episode Seizures versus Usual Care on Clinical Outcome and Safety Profile Aspects of the Thai Experience.
J Epilepsy Res
December 2024
Neurological Surgery Unit, Department of Surgery, Phramongkutklao Hospital, Bangkok, Thailand.
Background And Purpose: Epilepsy increases poor outcomes in patients with post-traumatic brain injury and brain tumor-related epilepsy, for whom early seizure control is essential. Perampanel (PER) was a known third-generation antiepileptic drug for treatment all types of seizures. The objective of the study is to compare clinical outcomes and safety of PER administration as monotherapy.
View Article and Find Full Text PDFEfficacy, safety, and tolerability of adjunctive perampanel in the treatment of pediatric patients aged 4-18 years with epilepsy: A single-center, retrospective, observational real-world study.
Brain Dev
November 2024
Department of Pediatrics, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China. Electronic address:
Purpose: To observe the efficacy, safety, and tolerability of perampanel (PER) as add-on therapy in children aged 4-18 years with epilepsy in a real-world environment.
Methods: A single-center, retrospective, observational study was conducted at the First Affiliated Hospital of Fujian Medical University enrolling children with epilepsy aged 4-18 years who received PER as add-on therapy from January 2021 to November 2022 with 12 months of follow-up. Outcomes included 3-, 6- and 12-month retention, seizure freedom, responder rates, and adverse events (AEs) throughout follow-up.
Response to amoxicillin and perampanel in infantile Alexander disease.
Epilepsia Open
December 2024
Epilepsy Unit. Hospital de la Santa Creu i Sant Pau, Barcelona, UAB, Barcelona, Spain.
Article Synopsis
- - Type I Alexander disease is a severe neurological disorder that causes issues like seizures and developmental problems starting in early childhood, linked to a mutation in the GFAP gene.
- - Although there's no cure, some treatments like ceftriaxone and amoxicillin have shown mild symptomatic improvement in patients by affecting glutamate levels in the brain.
- - In a case study, a patient with severe irritability and seizures improved significantly after treatment with amoxicillin and perampanel, suggesting a potential role for glutamate-modulating drugs in treating this condition.
Real-world effectiveness and safety of perampanel for children and adolescents with epilepsy: A meta-analysis with at least 1-year follow-up.
Seizure
November 2024
Department of Pediatrics, The First Affiliated Hospital of Fujian Medical University, Fuzhou, PR China. Electronic address:
Background: Perampanel, the first third-generation anti-seizure medication targeting the AMPA receptor, has been used in the treatment of patients with focal seizures, with or without secondary generalized seizures, and primary generalized tonic-clonic seizures. This study focused on the effectiveness and safety of perampanel for pediatric patients with at least 1-year follow-up in real-world settings.
Methods: We systematically searched PubMed, EMBASE, and Web of Science for real-world studies published before April 27, 2024.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!